Yingjie Zhang
+
Gender:Male
Education Level:Postgraduate (Doctoral)
Alma Mater:山东大学
Paper Publications
- [11] 丁钦阁. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. BIOORGANIC CHEMISTRY, 104, 2020.
- [12] 闫玉刚. In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875. DRUG DEVELOPMENT RESEARCH, 81, 708, 2020.
- [13] 许启富. Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. Front. Cell Dev. Biol., 8, 2020.
- [14] 赵春龙. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opinion on Therapeutic Patents, 30, 263, 2020.
- [15] 曹江营. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. Molecules, 25, 2020.
- [16] xuwenfang , Yingjie Zhang and 董航. Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules, 24, 2407, 2019.
- [17] Yingjie Zhang and 梁学武. Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. Future Medicinal Chemistry, 11, 1849, 2019.
- [18] liuxinyong , xuwenfang and Yingjie Zhang. Discovery of N-Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. J. Med. Chem, 2014.
- [19] xuwenfang and Yingjie Zhang. Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. Rsc Adv., 2013.
- [20] xuwenfang and Yingjie Zhang. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem. Biol. Drug Des, 2013.